OOIR: Observatory of International Research

Papers

(The H4-Index of Medicinal Research Reviews is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications	234
The role of hypoxia‐inducible factor 1 in tumor immune evasion	156
Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)	148
Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress‐ and aging‐related diseases	148
Molecular targeting therapies for neuroblastoma: Progress and challenges	142
Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today?	135
Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention	133
Understanding the tumor microenvironment for effective immunotherapy	128
Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions	115
Mechanisms of melanocyte death in vitiligo	107
Small molecules regulating reactive oxygen species homeostasis for cancer therapy	105
Biologically active isoquinoline alkaloids covering 2014–2018	105
A review in radiomics: Making personalized medicine a reality via routine imaging	103
Tripterygium wilfordii: An inspiring resource for rheumatoid arthritis treatment	100
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology	81
Therapeutic potential of phenylethanoid glycosides: A systematic review	79
Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure‐activity relationship	79
Phytochemistry and cardiovascular protective effects of Huang‐Qi (Astragali Radix)	78
Flavonoids as antiobesity agents: A review	78
The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases	76
Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug‐resistant infections	76
Emerging carrier‐free nanosystems based on molecular self‐assembly of pure drugs for cancer therapy	73
Emerging roles of SIRT6 in human diseases and its modulators	71
What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design	71
Emerging use of senolytics and senomorphics against aging and chronic diseases	70

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases	69
Autophagy and cardiac diseases: Therapeutic potential of natural products	68
Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: A therapeutic target to control intestinal inflammation	67
Skp2 in the ubiquitin‐proteasome system: A comprehensive review	64
Bioactive polymeric scaffolds for osteogenic repair and bone regenerative medicine	63
The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy	62
COVID‐19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays	61
Direct targeting of β‐catenin in the Wnt signaling pathway: Current progress and perspectives	58
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing	57
Reinvigorating exhausted CD8⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy	56
Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review	54
Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications	51
Development of anti‐influenza agents from natural products	49
Biologically active indolizidine alkaloids	47
Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases	47
Strategies for designing proteolysis targeting chimaeras (PROTACs)	46
KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential	46
Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism	46
The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases	44
Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition	44